Related Experiment Video

Updated: May 24, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors]

Szilvia Török1, Balázs Döme

  • 1Országos Korányi TBC és Pulmonológiai Intézet, Tumorbiológiai Osztály, Budapest, Hungary. szilvia.torok@koranyi.hu

Magyar Onkologia
|March 10, 2012
PubMed

Insights

Multi-target antiangiogenic tyrosine kinase inhibitors (TKIs) show promise in cancer treatment by blocking tumor vessel growth. Further research is needed to optimize their use and understand complex signaling pathways.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Tumor progression relies on functional blood vasculature.
  • Key signaling pathways involve VEGF, PDGF, and FGF tyrosine kinase receptors.
  • Receptor tyrosine kinase inhibitors (RTKIs) have emerged as a significant therapeutic strategy.

Purpose of the Study:

  • To discuss the mechanisms of action of multi-target antiangiogenic TKIs.
  • To review experimental and clinical study results of these inhibitors.
  • To identify current challenges and future directions in the field.

Main Methods:

  • Review of published experimental and clinical studies on multi-target antiangiogenic TKIs.
  • Analysis of signaling pathways involving VEGF, PDGF, and FGF tyrosine kinase receptors.
  • Discussion of mechanisms of action and therapeutic outcomes.

Main Results:

  • Multi-target antiangiogenic TKIs have demonstrated notable achievements.
  • These drugs are currently used in clinical practice for specific patient populations.
  • Significant progress has been made in understanding RTKIs.

Conclusions:

  • Multi-target antiangiogenic TKIs represent a promising therapeutic approach.
  • Challenges include optimizing drug combinations, dosages, and biomarker selection.
  • Further investigation into PDGFR and FGFR signaling in angiogenesis is crucial.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...